Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo

European Journal of Pharmacology

Volumn 555, Issue 1, 2007, Pages 8-16

  Yang, Xiaodong ^a   Yates, Marla L ^a   Candelore, Mari R ^a   Feeney, William ^a   Hora, Don ^a   Kim, Ron M ^a   Parmee, Emma R ^a   Berger, Joel P ^a   Zhang, Bei B ^a   Qureshi, Sajjad A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dog Glucagon Receptor; Glucagon; Receptor Antagonist

Indexed keywords

4 [[(4 TERT BUTYLCYCLOHEXYL)[1 METHYL 5 (TRIFLUOROMETHYL) 1H BENZIMIDAZOL 2 YL]AMINO]METHYL] N 1H TETRAZOL 5 YLBENZAMIDE; 4 [[9 TERT BUTYL 2 OXO 3 [4 (TRIFLUOROMETHOXY)PHENYL] 1,3 DIAZASPIRO[5.5]UNDEC 1 YL]METHYL] N 1H TETRAZOL 5 YLBENZAMIDE; AMIDE; AMINO ACID; COMPLEMENTARY DNA; CYCLIC AMP; GLUCAGON; GLUCAGON RECEPTOR; GLUCAGON RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; N [3 CYANO 6 (1,1 DIMETHYLPROPYL) 4, 5, 6, 7 TETRAHYDRO 1 BENZOTHIEN 2 YL] 2 ETHYLBUTANAMIDE; NUCLEOTIDE; RNA; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL MEMBRANE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; DRUG MECHANISM; EXPERIMENTAL DOG; GENE EXPRESSION; GENETIC CONSERVATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN VERSUS ANIMAL COMPARISON; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LIVER; MALE; MOLECULAR CLONING; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RODENT; SEQUENCE HOMOLOGY; SPECIES COMPARISON;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BLOOD GLUCOSE; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; DNA, COMPLEMENTARY; DOGS; GLUCAGON; HYPOGLYCEMIC AGENTS; LIVER; MALE; MOLECULAR SEQUENCE DATA; RECEPTORS, GLUCAGON; SEQUENCE ALIGNMENT;

EID: 33845808714     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.033     Document Type: Article

References (53)

1. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
2. Bockaert J., Marin P., Dumuis A., and Fagni L. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett. 546 (2003) 65-72
3. Bockaert J., Roussignol G., Becamel C., Gavarini S., Joubert L., Dumuis A., Fagni L., and Marin P. GPCR-interacting proteins (GIPs): nature and functions. Biochem. Soc. Trans. 32 (2004) 851-855
4. Burcelin R., Li J., and Charron M.J. Cloning and sequence analysis of the murine glucagon receptor-encoding gene. Gene 164 (1995) 305-310
5. Burcelin R., Katz E.B., and Charron M.J. Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Diabetes Metab. 22 (1996) 373-396
6. Cascieri M.A., Koch G.E., Ber E., Sadowski S.J., Louizides D., De Laszlo S.E., Hacker C., Hagmann W.K., Maccoss M., Chicchi G.G., and Vicario P.P. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J. Biol. Chem. 274 (1999) 8694-8697
7. Catchpole B., Ristic J.M., Fleeman L.M., and Davison L.J. Canine diabetes mellitus: can old dogs teach us new tricks?. Diabetologia 48 (2005) 1948-1956
8. Cherrington A.D., Chiasson J.L., Liljenquist J.E., Lacy W.W., and Park C.R. Control of hepatic glucose output by glucagon and insulin in the intact dog. Biochem. Soc. Symp. (1978) 31-45
9. Cherrington A.D., Edgerton D., and Sindelar D.K. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia 41 (1998) 987-996
10. Chicchi G.G., Graziano M.P., Koch G., Hey P., Sullivan K., Vicario P.P., and Cascieri M.A. Alterations in receptor activation and divalent cation activation of agonist binding by deletion of intracellular domains of the glucagon receptor. J. Biol. Chem. 272 (1997) 7765-7769
11. Chu C.A., Wiernsperger N., Muscato N., Knauf M., Neal D.W., and Cherrington A.D. The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis. Metabolism 49 (2000) 1619-1626
12. Consoli A. Role of liver in pathophysiology of NIDDM. Diabetes Care 15 (1992) 430-441
13. Dailey G. Insulin secretagogues: who, what, when, and how?. Curr. Diab. Rep. 5 (2005) 329-332
14. Davidson M.B., and Peters A.L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am. J. Med. 102 (1997) 99-110
15. Davison L.J., Catchpole B., Kennedy L.J., Barnes A., Thomson W., and Ollier W.E. Research into canine diabetes mellitus. Vet. Rec. 152 (2003) 148
16. De Laszlo S.E., Hacker C., Li B., Kim D., Maccoss M., Mantlo N., Pivnichny J.V., Colwell L., Koch G.E., Cascieri M.A., and Hagmann W.K. Potent, orally absorbed glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 9 (1999) 641-646
17. Djuric S.W., Grihalde N., and Lin C.W. Glucagon receptor antagonists for the treatment of type II diabetes: current prospects. Curr. Opin. Investig. Drugs 3 (2002) 1617-1623
18. Dobbins R.L., Connolly C.C., Neal D.W., Palladino L.J., Parlow A.F., and Cherrington A.D. Role of glucagon in countering hypoglycemia induced by insulin infusion in dogs. Am. J. Physiol. 261 (1991) E773-E781
19. Duffy J.L., Kirk B.A., Konteatis Z., Campbell E.L., Liang R., Brady E.J., Candelore M.R., Ding V.D., Jiang G., Liu F., Qureshi S.A., Saperstein R., Szalkowski D., Tong S., Tota L.M., Xie D., Yang X., Zafian P., Zheng S., Chapman K.T., Zhang B.B., and Tata J.R. Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor. Bioorg. Med. Chem. Lett. 15 (2005) 1401-1405
20. Edgerton D.S., Cardin S., Neal D., Farmer B., Lautz M., Pan C., and Cherrington A.D. Effects of hyperglycemia on hepatic gluconeogenic flux during glycogen phosphorylase inhibition in the conscious dog. Am. J. Physiol: Endocrinol. Metab. 286 (2004) E510-E522
21. Edgerton D.S., Neal D.W., Scott M., Bowen L., Wilson W., Hobbs C.H., Leach C., Sivakumaran S., Strack T.R., and Cherrington A.D. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54 (2005) 1164-1170
22. Jacobson P.B., Von Geldern T.W., Ohman L., Osterland M., Wang J., Zinker B., Wilcox D., Nguyen P.T., Mika A., Fung S., Fey T., Goos-Nilsson A., Grynfarb M., Barkhem T., Marsh K., Beno D.W., Nga-Nguyen B., Kym P.R., Link J.T., Tu N., Edgerton D.S., Cherrington A., Efendic S., Lane B.C., and Opgenorth T.J. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J. Pharmacol. Exp. Ther. 314 (2005) 191-200
23. Jelinek L.J., Lok S., Rosenberg G.B., Smith R.A., Grant F.J., Biggs S., Bensch P.A., Kuijper J.L., Sheppard P.O., Sprecher C.A., et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 259 (1993) 1614-1616
24. Jiang G., and Zhang B.B. Glucagon and regulation of glucose metabolism. Am. J. Physiol: Endocrinol. Metab. 284 (2003) E671-E678
25. Johnson D.G., Goebel C.U., Hruby V.J., Bregman M.D., and Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215 (1982) 1115-1116
26. Kim R., Chang J., Rouse E., Andersen D., Beconi M., Brady E., Candelore M., D-Yang Q., Ding V., Dragovic J., Jiang G., Lin Z., Mock S., Qureshi S.A., Saperstein R., Szalkowski D., Tamvakopoulos C., Teferra Y., Tong S., Tota L., Wright M., Yang X., Zheng S., Hammond M., Tata J., Chapman K., Zhang B., and Parmee E. Potent and selective benzimidazole glucagon receptor antagonists for the treatment of type 2 diabetes. 230th American Chemical Society National Meeting, San Diego, California (2005)
27. Kurukulasuriya R., and Link J.T. Progress towards glucagon receptor antagonist therapy for Type 2 diabetes. Expert Opin. Ther. Pat. 15 (2005) 1739-1749
28. Kurukulasuriya R., Sorensen B.K., Link J.T., Patel J.R., Jae H.S., Winn M.X., Rohde J.R., Grihalde N.D., Lin C.W., Ogiela C.A., Adler A.L., and Collins C.A. Biaryl amide glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 14 (2004) 2047-2050
29. Lenzen G., Pietri-Rouxel F., Drumare M.F., Amiard A., Guillot S., Archimbault P., and Strosberg A.D. Genomic cloning and species-specific properties of the recombinant canine beta3-adrenoceptor. Eur. J. Pharmacol. 363 (1998) 217-227
30. Lok S., Kuijper J.L., Jelinek L.J., Kramer J.M., Whitmore T.E., Sprecher C.A., Mathewes S., Grant F.J., Biggs S.H., Rosenberg G.B., et al. The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene 140 (1994) 203-209
31. Macneil D.J., Occi J.L., Hey P.J., Strader C.D., and Graziano M.P. Cloning and expression of a human glucagon receptor. Biochem. Biophys. Res. Commun. 198 (1994) 328-334
32. Madsen P., Ling A., Plewe M., Sams C.K., Knudsen L.B., Sidelmann U.G., Ynddal L., Brand C.L., Andersen B., Murphy D., Teng M., Truesdale L., Kiel D., May J., Kuki A., Shi S., Johnson M.D., Teston K.A., Feng J., Lakis J., Anderes K., Gregor V., and Lau J. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J. Med. Chem. 45 (2002) 5755-5775
33. Mcnally T., Grihalde N.D., Pederson T.M., Ogiela C.A., Djuric S.W., Collins C.A., Lin C.W., and Reilly R.M. Cloning and characterization of the glucagon receptor from cynomologous monkey. Peptides 25 (2004) 1171-1178
34. Muller W.A., Faloona G.R., Aguilar-Parada E., and Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283 (1970) 109-115
35. Nelson R., Spann D., Elliott D., Brondos A., and Vulliet R. Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats. J. Vet. Intern. Med. 18 (2004) 18-24
36. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., and Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
37. Parker J.C., Mcpherson R.K., Andrews K.M., Levy C.B., Dubins J.S., Chin J.E., Perry P.V., Hulin B., Perry D.A., Inagaki T., Dekker K.A., Tachikawa K., Sugie Y., and Treadway J.L. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes 49 (2000) 2079-2086
38. Parkinson C., and Grasso P. The use of the dog in toxicity tests on pharmaceutical compounds. Human Exp. Toxicol. 12 (1993) 99-109
39. Petersen K.F., and Sullivan J.T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44 (2001) 2018-2024
40. Qureshi S.A., Candelore M.R., Xie D., Yang X., Tota L.M., Ding V.D., Li Z., Bansal A., Miller C., Cohen S.M., Jiang G., Brady E., Saperstein R., Duffy J.L., Tata J.R., Chapman K.T., Moller D.E., and Zhang B.B. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53 (2004) 3267-3273
41. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., and Jaspan J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 64 (1987) 106-110
42. Saitou N., and Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4 (1987) 406-425
43. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
44. Shah P., Vella A., Basu A., Basu R., Schwenk W.F., and Rizza R.A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 85 (2000) 4053-4059
45. Shen D.M., Zhang F., Brady E.J., Candelore M.R., Dallas-Yang Q., Ding V.D., Dragovic J., Feeney W.P., Jiang G., Mccann P.E., Mock S., Qureshi S.A., Saperstein R., Shen X., Tamvakopoulos C., Tong X., Tota L.M., Wright M.J., Yang X., Zheng S., Chapman K.T., Zhang B.B., Tata J.R., and Parmee E.R. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 15 (2005) 4564-4569
46. Sloop K.W., Michael M.D., and Moyers J.S. Glucagon as a target for the treatment of Type 2 diabetes. Expert Opin. Ther. Targets 9 (2005) 593-600
47. Uchino H., Kim T., Lam T.K., Yoshii H., Klement P., Williams W., Kawamori R., and Giacca A. FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism 54 (2005) 1250-1258
48. Unger R.H. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27 (1978) 1691-1709
49. Unger R.H., and Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1 (1975) 14-16
50. Unson C.G., Andreu D., Gurzenda E.M., and Merrifield R.B. Synthetic peptide antagonists of glucagon. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 4083-4087
51. Unson C.G., Gurzenda E.M., and Merrifield R.B. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides 10 (1989) 1171-1177
52. Wasserman D.H., Spalding J.A., Lacy D.B., Colburn C.A., Goldstein R.E., and Cherrington A.D. Glucagon is a primary controller of hepatic glycogenolysis and gluconeogenesis during muscular work. Am. J. Physiol. 257 (1989) E108-E117
53. Woerle H.J., Szoke E., Meyer C., Dostou J.M., Wittlin S.D., Gosmanov N.R., Welle S.L., and Gerich J.E. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am. J. Physiol: Endocrinol. Metab. 290 (2006) E67-E77